Kamada Ltd. (KMDA) News
Filter KMDA News Items
KMDA News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KMDA News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest KMDA News From Around the Web
Below are the latest news stories about KAMADA LTD that investors may wish to consider to help them evaluate KMDA as an investment opportunity.
Kamada Projects Double-Digit Growth for 2025, Expands Plasma OperationsThe latest announcement is out from Kamada ( (IL:KMDA) ). Kamada Ltd. has announced its financial guidance for 2024 and 2025, projecting continued double-digit profitable growth. In 2025, the company expects revenues of $178 million to $182 million and adjusted EBITDA of $38 million to $42 million, marking a significant increase from 2024 figures. Kamada plans to enhance its business through strategic growth pillars, including expanding plasma collection operations and advancing its pivotal Phas |
Kamada Affirms 2024 Financial Guidance and Announces Expected Continued Double-Digit Profitable Growth for 2025• Provides 2025 Annual Guidance of $178 - $182 Million in Revenue and $38 - $42 Million of Adjusted EBITDA, Representing Year-Over-Year Increase of 13% in Revenues and 19% in Adjusted EBITDA Based on Mid-Point of 2024 Annual Guidance• Expects to Achieve 2024 Guidance of $158 - $162 Million in Revenue and $32 - $35 Million of Adjusted EBITDA; 2024 Year-End Cash of $78 Million• Aiming to Secure New Business Development and M&A Transactions During 2025 that Leverage Overall Financial Strength and E |
Exploring High Growth Tech Stocks This January 2025As global markets wrapped up the year with moderate gains, driven by large-cap growth stocks and a technology-heavy rally, concerns over falling U.S. consumer confidence and declining durable goods orders have cast a shadow on economic optimism. In this context of mixed economic signals, identifying high-growth tech stocks requires careful consideration of their potential to thrive amidst fluctuating consumer sentiment and broader market dynamics. |
Exploring Undiscovered Gems with Potential This December 2024As December 2024 unfolds, global markets are navigating a complex landscape marked by cautious Federal Reserve commentary and political uncertainties, with smaller-cap indices experiencing notable declines. The Fed's recent rate cut and tempered expectations for future reductions have added to investor apprehension, impacting market sentiment across the board. In this environment, identifying stocks with strong fundamentals and resilience becomes crucial. Such undiscovered gems can offer... |
Kamada Ltd (KMDA) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Increased EBITDA ...Kamada Ltd (KMDA) reports a 10% revenue increase and raises full-year EBITDA guidance, despite challenges in clinical trials and market competition. |
Kamada: Q3 Earnings SnapshotREHOVOT, Israel (AP) — Kamada Ltd. (KMDA) on Wednesday reported third-quarter earnings of $3.9 million. The Rehovot, Israel-based company said it had net income of 7 cents per share. The results met Wall Street expectations. |
Kamada Reports Continued Profitable Growth with Strong Third Quarter and Nine Month 2024 Financial Results; Raises Full-Year Profitability GuidanceRevenues for Third Quarter of 2024 were $41.7 Million, up 10% Year-over-Year; Nine Month 2024 Total Revenues were $121.9 Million, up 15% Year-over-YearThird Quarter 2024 Adjusted EBITDA of $8.8 Million, Representing an 11% Increase Year-over-Year; Nine Month 2024 Adjusted EBITDA of $25.4 Million, up 43% Year-over-YearRobust Third Quarter and Nine Month Results and Positive Outlook for Remainder of 2024 Support Increased Adjusted EBITDA Guidance to $32 Million-$35 Million, a 12% Increase of the M |
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024REHOVOT, Israel and HOBOKEN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine-months ended September 30, 2024, prior to the open of the U.S. financial markets on Wednesday, November 13, 2024. Kamada management wil |
Kamada to Present at the Stifel 2024 Healthcare ConferenceREHOVOT, Israel and HOBOKEN, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that Amir London, Chief Executive Officer, will present a corporate overview at the Stifel 2024 Healthcare Conference, which will take place in New York, NY, on November 18 - 19, 2024. Mr. London is schedu |
Kamada Announces Expansion of Plasma Collection Operations in Texas with the Opening of New Site in HoustonNew Plasma Collection Center in Houston Now Open, with Planned Annual Collection Capacity of Approximately 50,000 Liters and an Estimated Annual Revenue Contribution of $8 Million to $10 Million at its Full CapacityCenter Will Collect Normal Source Plasma and Specialty Plasma, such as Anti-Rabies and Anti-D, and is Anticipated to be One of the Largest Sites for Specialty Plasma Collection in the U.S. The New Center Supports Kamada's Strategy and Development as a Leading Global Vertically-Integra |